Clinical Trials Logo

CLL/SLL clinical trials

View clinical trials related to CLL/SLL.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06319456 Recruiting - CLL/SLL Clinical Trials

A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.

Start date: April 7, 2024
Phase: Phase 3
Study type: Interventional

This is a global, multicenter, randomized, open-label, Phase III confirmatory study to investigate the efficacy and safety of Lisaftoclax (APG-2575) in combination with Acalabrutinib in patients with newly diagnosed CLL/SLL.

NCT ID: NCT06104566 Recruiting - CLL/SLL Clinical Trials

Global Trial in APG2575 for Patients With CLL/SLL

Start date: December 20, 2023
Phase: Phase 3
Study type: Interventional

This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors

NCT ID: NCT05920668 Recruiting - CLL/SLL Clinical Trials

Phase IV Observational Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Cell Lymphoma

Start date: July 1, 2023
Phase:
Study type: Observational

This was a multicenter observational study of Orelabrutinib in the treatment of CLL/SLL. Patients were treated with Orelabrutinib for 12 cycles. The primary end points were grade 3 hypertension and incidence of atrial fibrillation, and the secondary end points were improvement in abnormal markers, ORR,CR,PFS, and OS.

NCT ID: NCT05791409 Recruiting - CLL/SLL Clinical Trials

Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL

AETHER
Start date: April 10, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

In this study, efficacy and safety of 2 regimens that combine the CD3-CD20 T cell engager epcoritamab with venetoclax will be tested in relapsed/refractory CLL and SLL patients. The trial starts with phase I part to establish the recommended dose level (RDL) of epcoritamab in the combination with venetoclax for the phase II trial.

NCT ID: NCT05665062 Recruiting - Clinical trials for Mantle Cell Lymphoma

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

Start date: June 24, 2022
Phase: Phase 1
Study type: Interventional

This is a first-in-human phase 1 study of SYNCAR-001 + STK-009 in patients with CD19+ hematologic malignancies.

NCT ID: NCT05590702 Recruiting - CLL/SLL Clinical Trials

French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma in Real-World Settings

FOLLOW
Start date: November 11, 2022
Phase:
Study type: Observational [Patient Registry]

Chronic lymphocytic leukemia (CLL) is the most frequent form of leukemia in the Western World. The disease is characterized by the accumulation and proliferation of mature, monoclonal, CD5+ B-cells with specific immunophenotype in the peripheral blood (above 5x109/L), bone marrow and secondary lymphoid organs. Small lymphocytic leukemia (SLL) is characterized by similar tumor cells but without increased lymphocyte count. The management of these patients have considerably changed over the last decade. Indeed, beyond chemo-immunotherapy, multiple targeted therapies have been approved on the basis of phase 2 and randomized phase 3 clinical trials and have subsequently been used in daily practice. The management of patients with SLL is similar to that of those with CLL. In addition to therapeutic advances, the advent of new sequencing technologies has also identified CLL genetic features that are now being incorporated in patient routine evaluation. We here propose to set a large-scale prospective and non-interventional study including patients with symptomatic CLL/SLL with the aim to evaluate the real-world clinical management of these patients and to identify the impact of treatments and therapeutic trajectories on long-term outcome.

NCT ID: NCT05491044 Recruiting - CLL/SLL Clinical Trials

A Study of Orelabrutinib in CLL/SLL Patients Who Are Slowly Responding to Ibrutinib

Start date: January 1, 2022
Phase: Phase 2
Study type: Interventional

This is a single arm, multi-center study to evaluate the efficacy and safety of orelabrutinib for Chronic lymphocytic lymphoma(CLL)/small lymphocytic lymphoma (SLL) patients who are slowly responding to Ibrutinib switched to Orelabrutinib.

NCT ID: NCT05487651 Recruiting - B-cell Lymphoma Clinical Trials

Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies

ANCHOR2
Start date: October 1, 2022
Phase: Phase 1
Study type: Interventional

This study is a multi-center study to evaluate the safety of KUR-502 in subjects with refractory/relapsed B-cell NHL or leukemia (ALL or CLL).

NCT ID: NCT05269940 Recruiting - Clinical trials for Non Hodgkin Lymphoma

A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies

Start date: January 27, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

ZX-101A-202 is a Phase I, open-label, multicenter study, a single-agent dose-escalation and dose-expansion study of ZX-101A. It is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacokinetics, efficacy and antitumor activity of ZX-101A in patients with relapsed/refractory hematological malignancies.

NCT ID: NCT04775745 Recruiting - Clinical trials for Mantle Cell Lymphoma

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

Start date: July 19, 2021
Phase: Phase 1
Study type: Interventional

This is a phase I, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed or refractory B-cell malignancies. LP-168 is a small molecule inhibitor.